Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA

Melody Dehghan,¹ Gabriel Wong,¹ Edward Neuberger,¹ Cindy Kin,² Florian Rieder,³ K T Park¹

To cite: Dehghan M, Wong G, Neuberger E, *et al.* Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA. *BMJ Open Gastro* 2021;**8**:e000781. doi:10.1136/bmjgast-2021-000781

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjgast-2021-000781>).

Received 31 August 2021
Accepted 16 November 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Genentech Inc, South San Francisco, California, USA

²Department of Surgery, Stanford University School of Medicine, Stanford, California, USA

³Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Correspondence to
K T Park; park.kt@gene.com

ABSTRACT

Background Patients with Crohn's disease (CD) may develop fibrostenotic strictures. No currently available therapies prevent or treat fibrostenotic CD (FCD), making this a critical unmet need.

Aim To compare health outcomes and resource utilisation between CD patients with and without fibrostenotic disease.

Methods Patients aged ≥18 years with FCD and non-FCD between 30 October 2015 and 30 September 2018 were identified in the Truven MarketScan Commercial Claims and Encounters Database. We conducted 1:3 nearest neighbour propensity score matching on age, sex, malnutrition, payer type, anti-tumour necrosis factor use, and Charlson Comorbidity Index score. Primary outcomes up to 1 year from the index claim were ≥1 hospitalisation, ≥1 procedure, ≥1 surgery, and steroid dependency (>100 day supply). Associations between FCD diagnosis and outcomes were estimated with a multivariable logistic regression model. This study was exempt from institutional review board approval.

Results Propensity score matching yielded 11 022 patients. Compared with non-FCD, patients with FCD had increased likelihood of hospitalisations (17.1% vs 52.4%; $p<0.001$), endoscopic procedures (4.4% vs 8.6%; $p<0.001$), IBD-related surgeries (4.7% vs 9.1%; $p<0.001$), steroid dependency (10.0% vs 15.7%; $p<0.001$), and greater mean annual costs per patient (\$47 575 vs \$77 609; $p<0.001$). FCD was a significant risk factor for ≥1 hospitalisation (adjusted OR (aOR), 6.1), ≥1 procedure (aOR, 2.1), ≥1 surgery (aOR, 2.0), and steroid dependency (aOR, 1.7).

Conclusions FCD was associated with higher risk for hospitalisation, procedures, abdominal surgery, and steroid dependency. Patients with FCD had a greater mean annual cost per patient. FCD represents an ongoing unmet medical need.

INTRODUCTION

Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) with a relapsing and remitting disease course.¹ Various phenotypes of CD have been characterised according to the Montreal classification based on age at diagnosis, gastrointestinal (GI) tract location, and

Summary box

What is already known about this subject?

- ⇒ There are no available therapies to prevent or treat fibrostenotic Crohn's disease (CD).
- ⇒ High rates of intestinal surgery and recurrence of intestinal strictures hallmark this subpopulation of CD patients.
- ⇒ No large-scale real-world evidence exists describing the health outcomes and direct healthcare costs of fibrostenotic CD patients.

What are the new findings?

- ⇒ In a given year, compared to CD patients without fibrostenosis, patients with fibrostenosis are approximately twice as likely to be dependent on corticosteroids, have recurrent CD-related surgery or repeated endoscopies, and more than six times more likely to undergo multiple hospitalisations.
- ⇒ This study represents the first analysis to compare healthcare resource utilisation and costs between CD patients with and without fibrostenosis.
- ⇒ Costs for patients with fibrostenosis were more than US\$30 000 higher per year than for non-FCD patients overall and more than three times the mean annual inpatient costs per patient.

How might it impact on clinical practice in the foreseeable future?

- ⇒ Fibrostenotic CD represents a persistent unmet need and significant burden on individual patients and the healthcare system.

behaviour of the disease course.^{2–4} Stricturing is the result of ongoing chronic activation of myofibroblasts by inflammation in the GI lining.^{5–8} Despite newer therapies now available or in development for IBD, none are approved for the treatment of fibrosis in IBD, hallmarking a critical unmet medical need for affected patients with fibrostenotic CD (FCD).^{8–11}

Previous research indicates that >50% of patients with CD will develop intestinal strictures in their lifetimes.^{6,10} Although anti-inflammatory

medical therapy is the standard of care, the evolution of strictures in FCD is thought to have a parallel pathogenesis that requires add-on antifibrotic treatment.⁸⁹ In light of this, rates of intestinal surgery and recurrence of strictures after surgery remain high and unchanged in FCD.^{3 8 12–15} Furthermore, repeated interventional endoscopic procedures, such as balloon dilation, appear to be a temporising measure with limited long-term usefulness.^{11 16–20}

Understandably, intestinal stricture formation in FCD can be devastating to patients. Scarring from the strictures can lead to intestinal narrowing, ultimately culminating in clinical obstruction.^{14 21} Signs and symptoms of clinical obstruction may include abdominal pain, constipation, nausea and vomiting, and, notably, loss of appetite or inability to tolerate foods, leading to chronic malnutrition.²²

Considering the devastating consequences of untreated stricturing in FCD, it is important to effectively describe the unmet needs in this patient population by characterising health outcomes and costs of care associated with FCD. In this study, we aimed to compare the differences in health outcomes and direct healthcare costs between patients with FCD and patients with CD without clinical stricturing using a population-based data set in the USA.

METHODS

Data source

We performed a retrospective cohort analysis of CD patients using the 2015–2019 Truven MarketScan Commercial Claims and Encounters data set. This database consists of deidentified outpatient, inpatient, and pharmaceutical claims of approximately 40 to 50 million privately insured patients each year. It includes demographic characteristics (age, sex, and geographic region), detailed encounter data (hospital admissions, outpatient visits, and associated procedures), and pharmaceutical data (pharmaceutical claims, day supply, strength, and administrative method). Claims originate from more than 150 large employer-sponsored health insurance plans with patient coverage in all 50 states.

Study population

We selected a cohort of patients aged ≥ 18 years who received an inclusive CD diagnosis (FCD and CD without fibrostenotic symptoms (non-FCD)) between 30 October 2015 and 30 September 2018. To be initially identified as having IBD, patients had to have at least two distinct outpatient visits or one inpatient visit for IBD within 2 years (K50.xx and K51.xx). From this group, we identified patients as having CD if $\geq 80\%$ of distinct *International Statistical Classification of Diseases, Tenth Revision (ICD-10)* diagnosis codes were K50.xx.^{23 24} For patients to be classified as having FCD, they had to have at least two distinct outpatient visits or one inpatient visit for FCD within 2 years (K50.012, K50.112, K50.812, K50.912). These specific *ICD-10* codes were unique to CD-related intestinal obstruction, affecting either the small or the large bowel or both intestinal segments. The requirement of at least

two separate coding indicators in the outpatient setting or a hospitalisation for CD-related intestinal obstruction ensures a higher degree of confidence in identifying the FCD subpopulation of interest; similar approaches have reliably identified patient populations with IBD and other conditions using claims data sets.^{25 26} For patients diagnosed with FCD, the first FCD-related claim was the index claim (figure 1A). For patients diagnosed with non-FCD, the first CD without fibrostenotic symptoms-related claim was the index claim. We required that patients be continuously enrolled in their insurance plan for ≥ 6 months before the index claim and ≥ 12 months afterwards. Patients could not have any autoimmune disease during the study period (spondylitis (M459), nodosa (M300), psoriatic arthritis (L4054, L4059), plaque psoriasis (L400), Wegener (M3130), lupus (M3210), rheumatoid arthritis (M05.x, M06.x), polyangiitis (M317)) or any IBD claims ≥ 6 months before the index date.

Outcomes and covariates

The primary outcomes of interest were healthcare resource utilisation (HCRU) markers: steroid dependency (>100 day supply in a year,^{27 28} ≥ 1 hospitalisation, ≥ 1 GI procedure, and ≥ 1 surgery within a year). Secondary outcomes included mean annual costs per patient: inpatient, outpatient excluding emergency department (ED), outpatient ED, pharmacy, and total cost per patient per year. Patients were classified as receiving corticosteroids based on outpatient or pharmaceutical claims for agents administered orally (not including inhalation) or by injection. ICD and Current Procedural Terminology (CPT) codes were to identify patients undergoing GI procedures and surgeries and were validated by gastroenterologists specialised in IBD (online supplemental appendix).

The primary predictor of interest was FCD versus non-FCD diagnosis. Patients were classified as receiving biologic therapy based on outpatient pharmaceutical claims or Healthcare Common Procedure Coding System (HCPCS) J-codes including infliximab, adalimumab, and certolizumab, vedolizumab, and ustekinumab. Charlson Comorbidity Index (CCI) score was calculated using inpatient and outpatient claims from 6 months preceding the index claim.

Propensity score matching

To adjust for potential differences regarding baseline characteristics between cohorts, we propensity score matched each patient with FCD to three patients with non-FCD (1:3 ratio) using nearest neighbour matching with a 0.2 caliper. Propensity scores were developed based on age (years), sex, malnutrition (E40–E46 *ICD-10*), payer type (commercial, Medicare), biologic use (yes/no), and CCI score (0, 1, or ≥ 2). Propensity score matching was implemented using the proc PSMATCH module in SAS Studio 3.7 (SAS Institute; Enterprise edition). χ^2 and Student's t tests were used to assess the comparability of baseline characteristics between cohorts for categorical variables and continuous variables, respectively. Student's t tests were used to assess differences

Figure 1 Study design and matching algorithm. (A) Study timeline. (B) Study flow diagram with propensity score matching (PSM). CCI, Charlson Comorbidity Index; CD, Crohn's disease; FCD, fibrostenotic Crohn's disease; TNF, tumour necrosis factor; UC, ulcerative colitis.

in costs between cohorts. All tests for significance were performed at the $\alpha=0.05$ level.

Multivariable models

Multivariable logistic regression models were used to estimate the association between FCD diagnosis and steroid dependency, ≥ 1 hospitalisation, ≥ 1 GI procedure, and ≥ 1 surgery in the propensity score matched cohort. Covariates included FCD diagnosis, age (years), sex, US geographic region (south, north central, northeast, west,

unknown), malnutrition, payer type (commercial, Medicare), plan type (preferred provider organisation (PPO), consumer-directed/high deductible health plan (CDHP/HDHP), health maintenance organisation (HMO), point of service (POS), other, unknown), anti-TNF therapy use, and CCI score (0, 1, ≥ 2). Referent groups for categorical variables were patients with CD without fibrostenotic symptoms, male sex, southern region, no malnutrition, commercial payer type, PPO plan type, no anti-TNF

Table 1 Patient attrition	
	N (%)
Inclusion criteria	
≥1 inpatient or ≥2 outpatient IBD claims from 30 October 2015 to 30 September 2019	190 899
Crohn's disease diagnosis (>80% of claims for CD)	102 188 (53.5)
Continuous enrolment: 6 months before, 12 months after index date	63 519 (62.2)
Age ≥18 years	59 062 (93.0)
Exclusion criteria	
No autoimmune disease	55 767 (94.4)
No IBD claims in the pre-index period	44 501 (79.8)
Total CD cohort	44 501
FCD cohort	
≥1 inpatient or ≥2 outpatient claims of FCD (on separate days)	2769 (6.2)
CD, Crohn's disease; FCD, fibrostenotic Crohn's disease; IBD, inflammatory bowel disease.	

therapy use, and CCI score of 0. A critical value of 0.05 was specified a priori. All analyses were performed using SAS Studio 3.7 (Enterprise edition).

All authors had access to the study data and reviewed and approved the final manuscript. This study is a retrospective claims database analysis and exempt from institutional review board review.

RESULTS

Patient demographics

Between 30 October 2015 and 30 September 2019, 190 899 patients with data in the Truven MarketScan

database had claims for IBD (table 1). After relevant inclusion and exclusion criteria were applied, a cohort of 47 270 patients with CD was included in the study (44 501 with non-FCD and 2769 with FCD). Before propensity score matching, there were significant ($p<0.001$) differences between the non-FCD and the FCD cohorts. The FCD cohort was generally older and had higher rates of malnutrition, higher rates of anti-TNF therapy use, and higher CCI scores (online supplemental table 1).

After propensity score matching (figure 1B), 2769 patients with FCD were matched with 8253 patients with non-FCD. No significant differences ($p>0.05$, all variables) were observed between cohorts following propensity score matching (table 2). The mean age for both cohorts was 46.9 years, with equal proportions of men and women, and most patients had commercial insurance (87.9%). Of note, related to cost drivers specific to anti-TNF therapy, propensity score matching ensured no differences between groups when considering anti-TNF therapy use. Overall, few patients had malnutrition (4.6%), 36.5% had received anti-TNF therapy in the pre-index period, and most patients had a CCI score of 0 (50.4%).

Healthcare resource utilisation

Annual HCRU was calculated per patient (figure 2). The proportion of patients with ≥1 hospitalisation was significantly higher ($p>0.001$) in the FCD cohort (52.4%) than in the non-FCD cohort (17.1%). A similar trend was shown for steroid dependency, with 15.7% in the FCD cohort and 10.0% in the non-FCD cohort ($p<0.001$). The FCD cohort had a significantly ($p<0.001$) higher proportion of patients experiencing ≥1 endoscopic procedure (8.6%) compared with the non-FCD cohort (4.4%). Consistent with these findings, a higher percentage of

Table 2 Patient demographics after match

	Overall N=11 022	Non-FCD N=8253 (74.9%)	FCD N=2769 (25.1%)	P value
Age, mean (SD)	46.9 (16.4)	46.9 (16.4)	46.9 (16.6)	0.876
Female sex	5598 (50.8)	4200 (50.9)	1398 (50.5)	0.714
Malnutrition	502 (4.6)	363 (4.4)	139 (5.0)	0.175
Payer type				0.694
Commercial	9684 (87.9)	7257 (87.9)	2427 (87.7)	
Medicare	1338 (12.1)	996 (12.1)	342 (12.3)	
Anti-TNF therapy*	4021 (36.5)	3011 (36.5)	1010 (36.5)	0.993
CCI				0.994
0	5551 (50.4)	4154 (50.3)	1397 (50.5)	
1	2238 (20.3)	1677 (20.3)	561 (20.3)	
2+	3233 (29.3)	2422 (29.4)	811 (29.3)	

All data are n (%) unless otherwise stated.

*Anti-TNF therapy included adalimumab, certolizumab pegol, ustekinumab, vedolizumab, and infliximab.

CCI, Charlson Comorbidity Index; FCD, fibrostenotic Crohn's disease; TNF, tumour necrosis factor.

Figure 2 Proportion of annual healthcare resource utilisation between FCD and non-FCD. FCD, fibrostenotic Crohn's disease; IBD, inflammatory bowel disease.

patients with FCD (9.1%) than non-FCD (4.7%) had ≥ 1 IBD-related surgery.

Results of the logistic regression (figure 3) adjusting for baseline demographic (age, sex, geographic region, payer type, and plan type) and clinical (malnutrition status, anti-TNF therapy use, CCI score, and CCI category) characteristics found that patients with FCD had significantly higher odds of being hospitalised compared with patients with non-FCD (adjusted OR (aOR), 6.1; 95% CI, 5.3 to 7.0). Additionally, patients with FCD experienced significantly higher odds of steroid dependency (aOR, 1.7; 95% CI, 1.4 to 2.0) and of undergoing ≥ 1 GI procedure (aOR, 2.1; 95% CI, 1.7 to 2.6).

Costs

Annual mean per-patient costs were generally higher for patients with FCD than for patients with non-FCD. Total mean costs were significantly higher for the FCD group (mean, US\$77 609 (SD, US\$96 772)) than for the non-FCD group (US\$47 575 (\$74 656)) ($p < 0.001$). Inpatient, ED, and outpatient costs were all significantly higher in the FCD group ($p < 0.001$, all comparisons) (figure 4). The

Figure 3 Adjusted OR of HCRU between FCD and non-FCD. Covariates for regression include FCD, age (years), sex, region (south, north central, northeast, west, unknown), malnutrition, payer (CCAE, MDCR), plan type (PPO, CDHP/HDHP, HMO, POS, other, unknown), anti-TNF therapy use, CCI (0, 1, 2+). aOR, adjusted OR; CCAE, Claims and Encounters Data; CCI, Charlson Comorbidity Index; CDHP, consumer-driven health plan; FCD, fibrostenotic Crohn's disease; HCRU, healthcare resource utilisation; HDHP, high-deductible health plan; HMO, health maintenance organisation; IBD, inflammatory bowel disease; MDCR, Medicare; POS, point of service; PPO, preferred provider organisation; TNF, tumour necrosis factor.

Figure 4 Annual mean costs per patient between FCD and non-FCD. ED, emergency department; FCD, fibrostenotic Crohn's disease.

highest costs for patients with FCD were those associated with inpatient visits, whereas the highest for patients with non-FCD were outpatient costs. Additionally, pharmacy-related costs were slightly higher for patients with FCD than for patients with non-FCD (FCD, US\$18 040 (US\$29 129); non-FCD, US\$16 963 (US\$25 966)); however, this difference was not statistically significant ($p = 0.67$).

DISCUSSION

Intestinal stricture formation is a common occurrence in CD. Patients with FCD who are living with clinical obstruction are subject to significantly worse health outcomes and increased HCRU than patients without FCD. The findings of our study underscore the persistent unmet medical need in a significant subpopulation of patients with CD. The aims of this study were to characterise the differential health outcomes and healthcare costs in patients with FCD who had clinical obstruction. In unadjusted and adjusted analyses, compared with patients with non-FCD, patients with FCD had approximately twice the increased odds of steroid dependency, progressing to multiple abdominal surgeries, and repeated endoscopic procedures. Strikingly, acute care remains a common medical management requirement. We found that patients with FCD are at $>6\times$ the risk for multiple hospitalisations in a given year than non-FCD patients. In terms of direct costs to society, on average, HCRU costs for patients with FCD were more than US\$30 000 higher per year than for non-FCD patients overall and $>3\times$ the mean annual inpatient costs per patient.

No antifibrotic therapies have been approved to treat patients with FCD. Although available medical therapies for CD may mitigate symptoms related to inflammation, endoscopic or surgical intervention is often necessary for patients with obstructions caused by stricture lesions.^{8–11 22} Some studies have even implicated anti-TNF therapies in worsening stricture formation and the ensuing obstruction.^{29–31} This notion, however, has been disproven in serial ultrasound studies, the TREAT registry, and the CREOLE cohort.^{32 33} Our analysis highlights the persistent unmet medical need in these patients, who endure worse health outcomes and increased acute

care utilisation. In addition, to date, our study is the first to compare HCRU and costs between patients with FCD and non-FCD. A previous study evaluating the cost of CD showed correlation between worsening disease, FCD, and higher CD-related surgical exposure.³⁴ Patients with CD who undergo CD-related surgeries bear more than twice the burden of cost than patients with moderate to severe CD (US\$101 013 per patient per year (PPPY) vs US\$44 934 PPPY, respectively).³⁵ Furthermore, recent studies have posited that anti-inflammatory therapies approved for CD are not effective in reducing the morbidity associated with intestinal fibrosis and stricture formation, as evidenced by increasing or plateaued rates of intestinal surgery in CD in recent decades.^{3 8 12–15}

Strengths of this study are that it represents the largest real-world analysis in FCD to date. Additionally, we used propensity score matching to control for observable differences in the population. Using this approach, we detected a significant difference between FCD and non-FCD groups in the use of acute care services, especially hospitalisation. Limitations include capture of diagnosis through medical coding, which is subject to errors or missing data. Potential confounders, such as smoking status, and validation of diagnoses with radiologic studies such as MRI were not available in this dataset. For this analysis, differentiation between types of fibrostenosis (ie, inflammatory-type vs fibrotic-type) was not possible using available claims data. In addition, outcomes within claims databases may not be generalisable to the overall population, and certain data elements, such as clinical variables (eg, Montreal classification), may not be captured and controlled for. It is also likely that focusing on obstruction underestimated the impact and prevalence of FCD.

In conclusion, we found that patients with FCD had worse outcomes and higher costs of care than patients with non-FCD. Costs of care were driven by inpatient costs, supporting the high unmet medical need in this subgroup of CD patients. Future prospective longitudinal cohort studies may supplement findings in this study and may further describe areas of unmet need and treatment gaps in this patient population at high risk.

Acknowledgements Editorial support was provided by ApotheCom of San Francisco, CA.

Contributors MD, GW, EN, and KTP contributed to study design, conception, data analysis, and manuscript writing; CK and FR contributed to study design and interpretation of results and editing the manuscript; KTP was involved in obtaining funding source and overall study concept. All authors approved the final version of the manuscript. KTP is guarantor of the work.

Funding Funded by F. Hoffmann-La Roche Ltd.

Competing interests MD, GW, EN, and KTP were/are employees of Genentech, Inc, and received salary and stock options. MD and GW were no longer employees of Genentech, Inc at the time of manuscript completion. CK has nothing to disclose. FR is consultant to or on the advisory board of Agomab, Allergan, AbbVie, Boehringer Ingelheim, Celgene/BMS, CDISC, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley Charitable Trust, Index Pharma, Janssen, Koutif, Mestag, Metacrine, Morphic, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surrozen, Takeda, TechLab, Theravance, Thetis, and UCB and is funded by NIH, Helmsley Charitable Trust, Crohn's and Colitis Foundation, UCB, Pliant, BMS, Pfizer, Boehringer Ingelheim, Morphic, and Kenneth Rainin Foundation.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. Not applicable.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- 1 Crohns and Colitis Foundation of America. The facts about inflammatory bowel disease. New York, NY: Crohns and colitis Foundation of America, 2014. Available: <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf> [Accessed 9 Mar 2021].
- 2 Satsangi J, Silverberg MS, Vermeire S, *et al*. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006;55:749–53.
- 3 Cosnes J, Gower-Rousseau C, Seksik P, *et al*. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011;140:1785–94.
- 4 Gomollón F, Dignass A, Annesse V, *et al*. 3Rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management. *J Crohns Colitis* 2017;11:3–25.
- 5 Rieder F, Latella G, Magro F, *et al*. European Crohn's and colitis organisation topical review on prediction, diagnosis and management of Fibrostenosing Crohn's disease. *J Crohns Colitis* 2016;10:873–85.
- 6 Rieder F, Focchi C, Rogler G, Mechanisms RG. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. *Gastroenterology* 2017;152:340–50.
- 7 Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 2012;18:1028–40.
- 8 Latella G, Di Gregorio J, Flati V, *et al*. Mechanisms of initiation and progression of intestinal fibrosis in IBD. *Scand J Gastroenterol* 2015;50:53–65.
- 9 Latella G, Rogler G, Bamias G, *et al*. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. *J Crohns Colitis* 2014;8:1147–65.
- 10 Rieder F, Bettenworth D, Ma C, *et al*. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. *Aliment Pharmacol Ther* 2018;48:347–57.
- 11 Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. *Inflamm Bowel Dis* 2004;10:55–60.
- 12 Ma C, Moran GW, Benchimol EI, *et al*. Surgical rates for Crohn's disease are decreasing: a population-based time trend analysis and validation study. *Am J Gastroenterol* 2017;112:1840–8.
- 13 Bessissow T, Reinglas J, Aruljothya A, *et al*. Endoscopic management of Crohn's strictures. *World J Gastroenterol* 2018;24:1859–67.
- 14 Chang C-W, Wong J-M, Tung C-C, *et al*. Intestinal stricture in Crohn's disease. *Intest Res* 2015;13:19–26.
- 15 Cosnes J, Nion-Larmurier I, Beaugerie L, *et al*. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. *Gut* 2005;54:237–41.
- 16 Lan N, Stocchi L, Ashburn JH, *et al*. Outcomes of endoscopic balloon dilation vs surgical resection for primary ileocolic strictures in patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2018;16:1260–7.
- 17 Thienpont C, D'Hoore A, Vermeire S, *et al*. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. *Gut* 2010;59:320–4.

- 18 Di Nardo G, Oliva S, Passariello M, *et al*. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn's disease with stricture: a prospective, randomized, double-blind, controlled trial. *Gastrointest Endosc* 2010;72:1201–8.
- 19 Gustavsson A, Magnuson A, Blomberg B, *et al*. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. *Aliment Pharmacol Ther* 2012;36:151–8.
- 20 Bettenworth D, Gustavsson A, Atreja A, *et al*. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with Stricturing Crohn's disease. *Inflamm Bowel Dis* 2017;23:133–42.
- 21 Bettenworth D, Bokemeyer A, Baker M, *et al*. Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. *Gut* 2019;68:1115–26.
- 22 Bharadwaj S, Fleshner P, Shen B. Therapeutic armamentarium for Stricturing Crohn's disease: medical versus endoscopic versus surgical approaches. *Inflamm Bowel Dis* 2015;21:2194–213.
- 23 Keyashian K, Dehghan M, Sceats L, *et al*. Comparative incidence of inflammatory bowel disease in different age groups in the United States. *Inflamm Bowel Dis* 2019;25:1983–9.
- 24 Wren AA, Bensen R, Sceats L, *et al*. Starting young: trends in opioid therapy among US adolescents and young adults with inflammatory bowel disease in the Truven MarketScan database between 2007 and 2015. *Inflamm Bowel Dis* 2018;24:2093–103.
- 25 Solberg LI, Engebretson KI, Sperl-Hillen JM, *et al*. Are claims data accurate enough to identify patients for performance measures or quality improvement? the case of diabetes, heart disease, and depression. *Am J Med Qual* 2006;21:238–45.
- 26 Govani SM, Lipson R, Nouredin M, *et al*. Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts. *Am J Manag Care* 2018;24:e374–9.
- 27 Lichtenstein GR, Loftus EV, Isaacs KL, *et al*. ACG clinical guideline: management of Crohn's disease in adults. *Am J Gastroenterol* 2018;113:481–517.
- 28 Park KT, Sceats L, Dehghan M, *et al*. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. *Aliment Pharmacol Ther* 2018;48:340–6.
- 29 Louis E, Boverie J, Dewit O, *et al*. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. *Acta Gastroenterol Belg* 2007;70:15–19.
- 30 Zorzi F, Zuzzi S, Onali S, *et al*. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. *Aliment Pharmacol Ther* 2012;35:1397–407.
- 31 Vasilopoulos S, Kugathasan S, Saeian K. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. *Am J Gastroenterol* 2000;95:2503.
- 32 Lichtenstein GR, Feagan BG, Cohen RD, *et al*. Serious infections and mortality in association with therapies for Crohn's disease: treat registry. *Clin Gastroenterol Hepatol* 2006;4:621–30.
- 33 Bouhnik Y, Carbonnel F, Laharie D, *et al*. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. *Gut* 2018;67:53–60.
- 34 Rao BB, Click BH, Koutroubakis IE, *et al*. The cost of Crohn's disease: varied health care expenditure patterns across distinct disease trajectories. *Inflamm Bowel Dis* 2017;23:107–15.
- 35 Manceur AM, Ding Z, Muser E, *et al*. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs. *J Med Econ* 2020;23:1092–101.